Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of Age.
Ruiz-Guiñazú J, Le Gars M, Cárdenas V, Vaissière N, Sadoff J, Truyers C, Hendriks J, Scheper G, de Groot AM, Struyf F, Schuitemaker H, Douoguih M. Ruiz-Guiñazú J, et al. Among authors: scheper g. J Pediatric Infect Dis Soc. 2024 Nov 27;13(11):599-601. doi: 10.1093/jpids/piae098. J Pediatric Infect Dis Soc. 2024. PMID: 39340467 Free PMC article.
Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines.
Kristyanto H, Slaets L, Braams E, Scheys I, Heesbeen R, Cárdenas V, Shukarev G, Scheper G, Sadoff J, Lühn K, Schuitemaker H, Struyf F, Hendriks J. Kristyanto H, et al. Among authors: scheper g. J Thromb Haemost. 2024 Dec;22(12):3532-3541. doi: 10.1016/j.jtha.2024.08.019. Epub 2024 Sep 13. J Thromb Haemost. 2024. PMID: 39278600 Free article.
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial.
Rezelj VV, Paddenburg F, Diegbe ME, Nangosyah J, Reisinger EC, Hu W, Truyers C, Scheper G, Le Gars M, Hendriks J, Struyf F, Douoguih M, Schuitemaker H, Ruiz-Guiñazú J. Rezelj VV, et al. Among authors: scheper g. Vaccines (Basel). 2024 Oct 3;12(10):1136. doi: 10.3390/vaccines12101136. Vaccines (Basel). 2024. PMID: 39460303 Free PMC article.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Hardt K, et al. Among authors: scheper g. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13. Lancet Infect Dis. 2022. PMID: 36113538 Free PMC article. Clinical Trial.
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Sadoff J, Le Gars M, Brandenburg B, Cárdenas V, Shukarev G, Vaissiere N, Heerwegh D, Truyers C, de Groot AM, Jongeneelen M, Kaszas K, Tolboom J, Scheper G, Hendriks J, Ruiz-Guiñazú J, Struyf F, Van Hoof J, Douoguih M, Schuitemaker H. Sadoff J, et al. Among authors: scheper g. Vaccine. 2022 Jul 30;40(32):4403-4411. doi: 10.1016/j.vaccine.2022.05.047. Epub 2022 Jun 3. Vaccine. 2022. PMID: 35667914 Free PMC article.
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.
Ong-Lim AL, Shukarev G, Trinidad-Aseron M, Caparas-Yu D, Greijer A, Duchene M, Scheper G, van Paassen V, Le Gars M, Cahill CP, Schuitemaker H, Douoguih M, Jacquet JM. Ong-Lim AL, et al. Among authors: scheper g. Hum Vaccin Immunother. 2022 Nov 30;18(5):2044255. doi: 10.1080/21645515.2022.2044255. Epub 2022 Mar 28. Hum Vaccin Immunother. 2022. PMID: 35344464 Free PMC article. Clinical Trial.
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J, Custers J, Scheper G, Robb ML, Treanor J, Ryser MF, Barouch DH, Swann E, Marovich MA, Neuzil KM, Corey L, Stoddard J, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Sadoff J, et al. Among authors: scheper g. N Engl J Med. 2022 Mar 3;386(9):847-860. doi: 10.1056/NEJMoa2117608. Epub 2022 Feb 9. N Engl J Med. 2022. PMID: 35139271 Free PMC article. Clinical Trial.
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Sadoff J, et al. Among authors: scheper g. N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21. N Engl J Med. 2021. PMID: 33882225 Free PMC article. Clinical Trial.
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H. Sadoff J, et al. Among authors: scheper g. N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13. N Engl J Med. 2021. PMID: 33440088 Free PMC article. Clinical Trial.
94 results